AAV Vector Production in Scalable Suspension Culture Systems
PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES
AAV Vector Production in Scalable Suspension Culture Systems
CELL & GENE | RNA | BIOLOGICS
Executive Summary
Transitioning an adeno-associated virus (AAV) program from research-grade adherent cultures to a commercially viable suspension system is a frequent point of failure for next-generation therapies. Franklin Biolabs provides a direct path to scalable, high-yield AAV production using robust suspension culture platforms in single-use bioreactors from 2L to 500L+, with a clear line of sight to larger scales. Our approach is built on a foundation of stable producer cell line development and process optimization, informed by decades of vector manufacturing experience. This methodology directly supports IND-enabling timelines of 18-24 months for our clients.
Frequently Asked Questions
What are the primary advantages of AAV scalable suspension systems over traditional adherent cultures for IND-enabling studies?
Suspension culture systems offer superior scalability, process control, and batch-to-batch consistency, which are required for generating the quantity and quality of vector needed for comprehensive IND-enabling toxicology studies. They eliminate the surface area limitations inherent to adherent platforms, enabling higher volumetric productivity and a more streamlined downstream purification process.
How does Franklin Biolabs ensure a smooth transition from a client’s research-scale protocol to a large-scale suspension process?
We employ a phase-appropriate process development strategy. This begins with optimizing parameters like transfection, media selection, and feed strategies at a small scale before confirming performance in scale-up runs. This data-driven approach minimizes risk and ensures the final process is robust, reproducible, and ready for GxP-compliant manufacturing.
What is the typical production volume for AAV vectors needed to support preclinical programs through FDA submission?
The required vector volume depends on the specific animal model, route of administration, and dose levels for the planned toxicology and biodistribution studies. Our platform is flexible, with production in single-use bioreactors ranging from 2L up to 500L+, ensuring sufficient material is produced for all nonclinical development activities leading to a successful IND filing.
The Strategic Shift to Suspension for Clinical Viability
The physical limitations of adherent cell culture present a significant bottleneck for AAV programs targeting clinical trials. Achieving the vector quantities required for nonclinical toxicology studies and subsequent clinical phases demands a manufacturing platform built for volumetric efficiency. Suspension culture systems in single-use bioreactors provide this solution, offering a controlled, reproducible environment for high-density cell growth and viral vector production.
A successful suspension process is contingent on the underlying cell line. The development of stable producer cell lines, engineered for high-yield Rep/Cap expression and vector packaging, is a foundational element for consistent, large-scale AAV manufacturing (PMID: 11991756). This biological groundwork is a prerequisite for any mechanically scalable hardware.
Process Development for Commercial-Scale AAV
Franklin Biolabs utilizes single-use bioreactors, providing flexibility in batch sizes from 2L to 500L+. Our process development services focus on key upstream and downstream parameters to create a manufacturing solution tailored to your specific AAV serotype and gene of interest.
-
Upstream Process Optimization: We refine transfection parameters and develop customized media and feed strategies to maximize volumetric productivity.
-
Downstream Purification: Our team can implement platform-based purification protocols or develop client-specific methods to meet stringent quality and purity requirements for in vivo use.
-
Analytical Rigor: The process is supported by a comprehensive suite of platform QC assays to characterize vector titer, purity, and potency, ensuring material meets all specifications for IND-enabling studies.
The principles of engineering a scalable production platform are universal across next-generation therapies. Insights from developing parallelized systems for LNP manufacturing, which achieved significantly higher production rates and superior in vivo potency, inform our approach to AAV process design (PMID: 34189917). The objective is always to build a process with the final clinical and commercial scale in mind. For a deeper look at our approach, our team discusses key factors for AAV programs in this technical webinar.
The continuity of scientific and process knowledge is a core component of our model. The same scientific leadership and principal scientists who architected these processes now lead them at Franklin Biolabs, ensuring uninterrupted program momentum.
This model ensures seamless program continuity for our partners. For instance, a collaboration initiated with the UPenn Vector Core in 2023 produced the foundational AAV vector for a partner’s gene therapy candidate now entering preclinical studies. The partnership and associated program knowledge transitioned without interruption to the Franklin Biolabs Research Vector Division along with the principal scientific staff.
This integration of historical expertise and purpose-built infrastructure within our >100,000 sq ft facility enables our partners to move from concept to IND submission efficiently.
For more information on our comprehensive manufacturing capabilities, please see our main service page: Large-Scale AAV Manufacturing and Process Development.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.